Statements (55)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:monoclonal_antibody
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:Stelara
|
gptkbp:activities |
inhibits IL-12 and IL-23
|
gptkbp:appointed_by |
subcutaneous injection
|
gptkbp:approves |
gptkb:2009
gptkb:FDA requires sterile water for injection |
gptkbp:class |
Ig G1 kappa monoclonal antibody
|
gptkbp:clinical_trial |
Phase 3
chronic inflammatory conditions |
gptkbp:contraindication |
active infections
hypersensitivity to the drug |
gptkbp:developed_by |
gptkb:Janssen_Pharmaceuticals
|
gptkbp:education |
advise on potential side effects
importance of follow-up appointments instruct on proper injection technique |
gptkbp:excretion |
primarily through the reticuloendothelial system
|
gptkbp:financial_performance |
stable for 24 hours at room temperature after reconstitution
|
gptkbp:formulation |
lyophilized powder for injection
|
gptkbp:frequency |
every 12 weeks after initial dose
|
https://www.w3.org/2000/01/rdf-schema#label |
ustekinumab
|
gptkbp:indication |
gptkb:ankylosing_spondylitis
gptkb:psoriatic_arthritis |
gptkbp:ingredients |
C_45 H_69 N_13 O_13 S
|
gptkbp:interacts_with |
immunosuppressants
live vaccines |
gptkbp:invention |
2028
|
gptkbp:is_monitored_by |
monitor for allergic reactions
monitor for signs of infection |
gptkbp:is_used_for |
treatment of psoriasis
treatment of ulcerative colitis treatment of Crohn's disease |
gptkbp:lifespan |
15 to 46 days
|
gptkbp:manager |
subcutaneous
|
gptkbp:marketed_as |
gptkb:Stelara
|
gptkbp:provides_information_on |
recommended for moderate to severe cases
|
gptkbp:research_areas |
gptkb:healthcare_organization
autoimmune diseases rheumatology dermatology |
gptkbp:side_effect |
fatigue
headache nausea rash increased risk of infections injection site reactions thrombocytopenia hypersensitivity reactions elevated liver enzymes |
gptkbp:storage |
refrigerated
|
gptkbp:targets |
gptkb:interleukin-23
interleukin-12 |
gptkbp:website |
abdomen or thigh
|
gptkbp:weight |
150 k Da
|